New drug combo shows promise for untreated CLL/SLL
NCT ID NCT05718869
First seen Nov 05, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with CLL or SLL. The goal is to see if this combination can kill more cancer cells than either drug alone. About 26 adults will take part, and researchers will measure how many achieve a complete response and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33146, United States
Conditions
Explore the condition pages connected to this study.